Key Points in Managing PLA2R-Associated Membranous Nephropathy

Key Points in Managing PLA2R-Associated Membranous Nephropathy

Saved in:

Bibliographic Details
Main Authors:	Raja Ramachandran, Vivekanand Jha, Bhadran Bose
Format:	Article
Language:	English
Published:	Elsevier 2024-08-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924017522
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Current research status of PLA2R and malignancy associated membranous nephropathy
by: Zhu Wan-ting, et al.
Published: (2021-01-01)

WCN25-1817 THE UNUSAL CASE SERIES OF PLA2R MEMBRANOUS NEPHROPATHY WITH PLA2R ANTIGEN ABSENT AND SERUM PLA2R ANTIBODY PRESENT
by: Anupam Agarwal, et al.
Published: (2025-02-01)

INVESTIGATION OF THE EFFECT OF PLA2R1 POLYMORPHISM IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
by: Aida Adıkozalova, et al.
Published: (2024-10-01)

PLA2R-associated membranous nephropathy associated with renal clear cell carcinoma: one case report
by: Xu Xiao-chang, et al.
Published: (2021-01-01)

The significance of anti-PLA2R antibody in the diagnosis and treatment of primary membranous nephropathy
by: XU Dong-mei, et al.
Published: (2019-01-01)

Serumanti-PLA2R antibody predicted treatment outcome in idiopathic membranous nephropathy
by: Zhang Xue-qin, et al.
Published: (2021-01-01)

Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence
by: Alexandre Destere, et al.
Published: (2024-01-01)

Double Trouble in the Basement! A Case of PLA2R-Associated Membranous Nephropathy with Atypical Anti-Glomerular Basement Membrane Disease
by: Renuka Tolani, et al.
Published: (2024-11-01)

Screening potential diagnostic biomarkers for PLA2R‑associated idiopathic membranous nephropathy by WGCNA analysis and LASSO algorithm
by: Jinxu Huang, et al.
Published: (2025-12-01)

Study on predictors for treatment efficacy of rituximab in patients with PLA2R-negative primary membranous nephropathy
by: XU Lili, HU Xiaofan, LI Hao, WANG Weiming
Published: (2025-06-01)

Case report: Coexistence of optic neuritis and primary anti-PLA2R-positive membranous nephropathy
by: Xi Wang, et al.
Published: (2025-03-01)

Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
by: Li XQ, et al.
Published: (2025-07-01)

Research progresson correlation of PLA2R1 and HLA gene polymorphisms with susceptibility toidiopathic membranous nephropathy
by: XIE Da-xing, et al.
Published: (2019-01-01)

Differences in serum anti-PLA2R antibody determination in Uygur patients with idiopathic membranous nephropathy in Xinjiang
by: ZHANG Jin, et al.
Published: (2018-01-01)

Diagnostic value of PLA2R, THSD7A and IgG subtypes in idiopathic membranous nephropathy
by: XUE Hen, et al.
Published: (2020-01-01)

Association of two polymorphisms rs3749117 and rs3749119 in PLA2R1 with idiopathic membranous nephropathy:A Meta-analysis
by: Sheng Qian, et al.
Published: (2021-01-01)

Clear cell renal cell carcinoma complicated with PLA2R-associated membranous nephropathy：three cases report and literature review
by: Sun Miao-xin, et al.
Published: (2025-02-01)

Clear cell renal cell carcinoma complicated with PLA2R-associated membranous nephropathy：three cases report and literature review
by: Sun Miao-xin, et al.
Published: (2025-02-01)

Pembrolizumab-Mediated Complete Remission of a PLA2R-Positive Paraneoplastic Membranous Nephropathy: A Case Report
by: Rayane Benyahia, et al.
Published: (2025-04-01)

Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy
by: Giuseppe Stefano Netti, et al.
Published: (2019-01-01)

Analysis of the correlation between serum anti-PLA2R antibodies and thromboembolic events in patients with idiopathic membranous nephropathy
by: Sun Miao-xin, et al.
Published: (2025-07-01)

Role of PLA2R domain antibodies and epitope spreading in risk stratification and prediction of proteinuria remission in primary membranous nephropathy
by: Xiran Zhang, et al.
Published: (2025-02-01)

WCN24-1092 Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy
by: Kezhi Zhou, et al.
Published: (2024-04-01)

PM2.5-induced oxidative stress upregulates PLA2R expression in the lung and is involved in the pathogenesis of membranous nephropathy through extracellular vesicles
by: Wang Zhang, et al.
Published: (2024-12-01)

How to Choose Treatment Regimens for Idiopathic Membranous Nephropathy Patients with PLA2R-Negative: A Single-Center Retrospective Cohort Study
by: Zhou Z, et al.
Published: (2025-05-01)

Corrigendum to “Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy” [Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188]
by: Maxime Teisseyre, et al.
Published: (2024-07-01)

WCN25-3960 OBSERVATIONAL ANALYSIS OF TREATMENT OUTCOMES AND ASSOCIATION OF PLA2R LEVELS IN PRIMARY MEMBRANOUS NEPHROPATHY IN A TERTIARY CARE CENTER OF EASTERN INDIA
by: Gopambuj Singh Rathod, et al.
Published: (2025-02-01)

WCN25-2664 Low-dose versus Standard-dose cyclical Cyclophosphamide and Steroids in the treatment of Primary Membranous Nephropathy- a randomized controlled trial
by: Raja Ramachandran, et al.
Published: (2025-02-01)

WCN25-3229 BREAKING DISEASE BARRIERS: A CASE OF ANTI-PLA2R POSITIVE MEMBRANOUS NEPHROPATHY FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
by: Neha Debnath, et al.
Published: (2025-02-01)

WCN25-4466 Baseline parameters of IgA Nephropathy Using the Oxford MEST Score: Insights from the I-TANGIBLE Registry
by: Kavita Yadav, et al.
Published: (2025-02-01)

WCN25-4036 Improved Outcomes with an Additional Rituximab Dose in Primary Membranous Nephropathy
by: Vinod Kumar, et al.
Published: (2025-02-01)

WCN25-950 CLINICAL PROFILE AND EFFECTIVENESS OF THERAPY IN PLA2R ASSOCIATED MEMBRANOUS GLOMERULONEPHRITIS: AN AMBISPECTIVE STUDY
by: Asheesh Kumar, et al.
Published: (2025-02-01)

WCN25-4122 Rituximab in Primary Membranous Nephropathy- three years outcome
by: Prabjot Kaur Johal, et al.
Published: (2025-02-01)

WCN25-843 FELZARTAMAB REDUCES aPLA2R Ab BY SELECTIVELY DEPLETING CD38+ PLASMA CELLS AND PLASMABLASTS, THE MAIN PATHOGENIC CELLULAR DRIVERS OF DISEASE IN PRIMARY MEMBRANOUS NEPHROPATHY (PMN)
by: Donna Flesher, et al.
Published: (2025-02-01)

WCN25-1613 GLUCOCORTICOID TOXICITY INDEX IN MEMBRANOUS NEPHROPATHY AND PODOCYTOPATHIES IN ADULT: A PILOT STUDY
by: RAJESH KUMAR, et al.
Published: (2025-02-01)

Dermatomyositis with membranous nephropathy
by: A Soylu, et al.
Published: (2001-04-01)

WCN25-4408 Clinical Outcomes of FSGS with Nephrotic Syndrome at 1-Year: Findings from the ITANGIBLE Registry
by: Kavita Yadav, et al.
Published: (2025-02-01)

Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome
by: David Massicotte Azarniouch, et al.
Published: (2024-10-01)

Erratum to “Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome” [Kidney International Reports Volume 9, Issue 10, October 2024, Pages 3053-3056]
by: David Massicotte-Azarniouch, et al.
Published: (2025-04-01)

Myeloperoxidase-Associated Membranous Nephropathy in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis
by: Kenta Tominaga, et al.
Published: (2024-07-01)